Private Capital Group’s Akari Therapeutics AKTX Stock Holding History

Private Capital Group’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Hold	0	–	–	–	2109
2021 Q1	–	Hold	0	–	–	–	2024
2020 Q4	–	Hold	0	–	–	–	2056
2020 Q3	–	Sell	-3	Closed	-$4.45K	–	1996
2020 Q2	$5K	Hold	3	–	–	﹤0.01%	1502
2020 Q1	$4K	Buy	3 +1	+50%	+$1.39K	﹤0.01%	1520
2019 Q4	$2K	Buy	+2	New	+$2.95K	﹤0.01%	1672

Other funds holding AKTX

OFW

Omnia Family Wealth Aventura, Florida $373M AUM 25.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Private Capital Group's AKTX Position: Q2 2021 in Review

Private Capital Group held its Akari Therapeutics (AKTX) position steady in Q2 2021 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2109.

Private Capital Group first reported a position in AKTX in Q4 2019 and has held it in 3 quarters since. The position peaked at $5K in Q2 2020. 12 funds tracked by Wall St. Rank hold AKTX as of Q2 2021.

Private Capital Group held 0 shares of Akari Therapeutics worth $0 as of Q2 2021.
Private Capital Group left its Akari Therapeutics share count unchanged in Q2 2021.
Akari Therapeutics made up ﹤0.01% of Private Capital Group's portfolio in Q2 2021, its #2109 holding.
Private Capital Group first reported a position in Akari Therapeutics in Q4 2019 and has held it in 3 quarters since.
Private Capital Group's Akari Therapeutics position peaked at $5K in Q2 2020.
12 funds tracked by Wall St. Rank held Akari Therapeutics as of Q2 2021.

Based on Private Capital Group's 13F filing for Q2 2021, filed 26 Jul 2021.